2017
DOI: 10.1371/journal.pone.0175969
|View full text |Cite
|
Sign up to set email alerts
|

Development of mismatch amplification mutation assays for the differentiation of MS1 vaccine strain from wild-type Mycoplasma synoviae and MS-H vaccine strains

Abstract: Mycoplasma synoviae is an economically significant pathogen in the poultry industry, inducing respiratory disease and infectious synovitis in chickens and turkeys, and eggshell apex abnormality in chickens. Eradication, medication and vaccination are the options for controlling M. synoviae infection. Currently there are two commercial, live, attenuated vaccines available against M. synoviae: the temperature sensitive MS-H vaccine strain and the NAD independent MS1 vaccine strain. Differentiation of vaccine str… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
10
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(10 citation statements)
references
References 16 publications
0
10
0
Order By: Relevance
“…The MS1 vaccine, which is well known to be NAD-independent, is presumed to have a different mechanism for its NAD-independent nature. The MS1 vaccine was developed by in vitro passaging of type strain ATCC 25204 (WVU1853) under laboratory conditions [8]. Because this type of strain is a parent strain of the MS1 vaccine, NAPRT or GPAT will not be present in the genome of the MS1 vaccine.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The MS1 vaccine, which is well known to be NAD-independent, is presumed to have a different mechanism for its NAD-independent nature. The MS1 vaccine was developed by in vitro passaging of type strain ATCC 25204 (WVU1853) under laboratory conditions [8]. Because this type of strain is a parent strain of the MS1 vaccine, NAPRT or GPAT will not be present in the genome of the MS1 vaccine.…”
Section: Discussionmentioning
confidence: 99%
“…In 1984, Yagihashi and Kato also discovered that MS can grow in an NAD-free broth [7]. However, although NAD-independent MS1 vaccine strain is now commercially available [8], the metabolic pathway that enables MS to grow without NAD remains unknown.…”
Section: Introductionmentioning
confidence: 99%
“…Vaccination against M. synoviae is performed especially in breeders and layers to prevent clinical signs and bacteria spread. Currently there are two commercialized live attenuated vaccines available against M. synoviae: the temperature sensitive MS-H vaccine strain and the NAD independent MS1 vaccine strain (Kreizinger et al, 2018). Interaction of these vaccines with other respiratory pathogens is documented.…”
Section: Diagnosismentioning
confidence: 99%
“…Recently, diff erentiation between M. synoviae vaccine and fi eld strains was performed with indirect ELISA based on OppF-C gene (Kordafshari et al, 2019). Furthermore, a melt-curve and agarose gel-based mismatch amplifi cation mutation assays (MAMA) was recently provided to discriminate the MS1 vaccine strain from the MS-H vaccine strain and wildtype M. synoviae isolates (Kreizinger et al, 2018). However, these assays are limited by the available facilities and the cost.…”
Section: Diagnosismentioning
confidence: 99%
“…Thus, far, the best way to prevent diseases caused by M. synoviae is pathogen eradication; however, this is very expensive and may be cost-prohibitive for farms in many countries and regions. Serological and molecular diagnosis, control using antibiotics, and immunization are generally implemented in farms (4)(5)(6).…”
Section: Introductionmentioning
confidence: 99%